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Abstract
G-proteins cycle between an inactive GDP-bound state and active GTP-bound state, serving as
molecular switches that coordinate cellular signaling. We recently used phage-display to identify a
series of peptides that bind Gα subunits in a nucleotide-dependent manner [Johnston, C. A., Willard,
F. S., Jezyk, M. R., Fredericks, Z., Bodor, E. T., Jones, M. B., Blaesius, R., Watts, V. J., Harden, T.
K., Sondek, J., Ramer, J. K., and Siderovski, D. P. (2005) Structure 13, 1069–1080]. Here we describe
the structural features and functions of KB-1753, a peptide that binds selectively to GDP·AlF4−- and
GTPγS-bound states of Gαi subunits. KB-1753 blocks interaction of Gαtransducin with its effector,
cGMP phosphodiesterase, and inhibits transducin-mediated activation of cGMP degradation.
Additionally, KB-1753 interferes with RGS protein binding and resultant GAP activity. A fluorescent
KB-1753 variant was found to act as a sensor for activated Gα in vitro. The crystal structure of
KB-1753 bound to Gαi1·GDP·AlF4− reveals binding to a conserved hydrophobic groove between
switch II and α3 helices, and, along with supporting biochemical data and previous structural
analyses, supports the notion that this is the site of effector interactions for Gαi subunits.
Heterotrimeric G-proteins serve as critical relays that transmit cues from extracellular stimuli
as diverse as neurotransmitters, hormones, photons, and odorants/tastants to intracellular
signaling cascades responsible for eliciting specific cellular effects (1,2). In the traditional
model of G-protein signaling, cell surface G-protein coupled receptors (GPCRs), upon
activation by the aforementioned stimuli, catalyze the exchange of GDP for GTP on the Gα
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subunit. This results in adoption of the active, GTP-bound Gα conformation, which dissociates
from the Gβγ dimer formerly bound to inactive, Gα·GDP as a heterotrimeric Gαβγ complex.
Gα·GTP and freed Gβγ then regulate a variety of downstream effectors by both individual and
coordinated mechanisms (1,2). The GTP-dependent conformational changes within Gα
required for effector binding are known for Gαs bound to adenylyl cyclase (3), Gαtransducin
(Gαt) bound to the gamma subunit of cGMP phosphodiesterase (PDEγ) (4), Gα13 bound to
p115RhoGEF (5), and Gαq bound to GRK2 (6). However, no effector-bound structure of
Gαi1–3 has yet been determined. Gα·GTP signaling to effectors is terminated by intrinsic GTP
hydrolysis activity of Gα, returning it to the GDP-bound conformation and Gβγ reassociation.
GTP hydrolysis can be dramatically enhanced by the family of proteins known as ‘regulators
of G-protein signaling’ (RGS), which serve as GTPase-accelerating proteins (GAPs) for Gα
subunits (7,8). This model of nucleotide cycling predicts that the duration and intensity of
signaling is ultimately determined by the lifetime of Gα in the activated, GTP-bound
conformation. Therefore, a complete understanding of the molecular determinants of the
guanine nucleotide cycle is of particular importance to understanding the temporal aspects
governing G-protein-mediated signal transduction.
We recently employed phage display technology to identify peptides capable of interacting
with Gα in a conformation-dependent manner (9,10). These peptides selectively bind Gα by
distinguishing key structural orientations of the critical ‘switch regions’ in Gα that govern
nucleotide exchange and hydrolysis and control interaction with regulatory proteins and
effectors (11). In addition to their discriminatory binding properties, these peptides can possess
intrinsic regulatory properties that provide insight into the regulation of Gα signaling. For
example, we recently described the molecular basis for the interaction of a GDP-selective
peptide, KB-752, with Gα·GDP (10). KB-752 serves as a guanine nucleotide exchange factor
(GEF) in vitro, and the structure of the Gα/KB-752 complex provided insight into the role of
switch II displacement in the mechanism of GPCR-mediated nucleotide exchange, a process
that remains largely elusive (12–14). Several other groups have also used similar techniques
to identify Gα- and Gβγ-binding peptides that have provided insight regarding the mechanics
of heterotrimeric G-protein signaling (15–18).
Here we describe the crystal structure of a peptide, KB-1753, that interacts exclusively with
activated Gαi subunits, including the closely related Gαtransducin. The structure of the KB-1753/
Gαi1·GDP·AlF4− complex reveals the molecular determinants of nucleotide selective binding
of KB-1753 to Gα, highlighting the importance of the disposition of the switch II helix.
KB-1753 competitively antagonizes the binding of PDEγ to Gαt, suggesting that KB-1753
binds in a similar fashion to that of effectors. Additionally, KB-1753 prevents RGS protein
binding and resultant GAP activity towards Gαi1 and Gαt. We also demonstrate the utility of
a fluorescently-modified KB-1753 to serve as a sensor for activated Gαi1 in vitro. Collectively,
our results represent the first structure of Gαi1 engaging an activation-state-selective target in
its effector-binding region and underscore the usefulness of the KB-1753 peptide as a tool for
studying G-protein signal transduction.
MATERIALS AND METHODS
Materials
Unless noted, all reagents were from Sigma. Peptides were synthesized by Anaspec (San Jose,
CA), except for the C-terminal cysteine variant of KB-1753 and PDEγ (63–87)
(GLGTDITVICPWEAFNHLELHELAQYGII), which were synthesized by the Tufts
University Core Facility (directed by Dr. Michael Berne).
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Oligonucleotides encoding KB-1753 were constructed with 5’-KpnI and 3’-BamHI overhangs:
sense: 5’-CGT CTT CTC GAG GTT ACT ACC ATG GTA TTT GGG TGG GTG AAG AAG
GTC GAC TTT CTC GAT GC-3’ and antisense: 5’-GAT CGC ATC GAG AAA GTC GAC
CTT CTT CAC CCA CCC AAA TAC CAT GGT AGT AAC CTC GAG AAG ACG GTA
C-3’. 100 ng of each primer were mixed, denatured, annealed (55°C for 1 min), and cooled
prior to ligation into KpnI/BamHI-digested pEYFP-N1 (Clontech). To avoid steric hindrance
to the KB-1753/Gα interaction by YFP, we inserted a flexible linker (Gly-Ser-Gly-Gly-Ser-
Gly) between KB-1753 and YFP by insertional mutagenesis (QuickChange; Stratagene) with
the following primers: sense: 5’-CGA CTT TCT CGA TGC GGA TCT GGT GGC TCA GGG
GAT CCA CCG GTC GCC-3’ and antisense: 5’-GGC GAC CGG TGG ATC CCC TGA GCC
ACC AGA TCC GCA TCG AGA AAG TCG -3’. The KB-1753-linker-YFP open-reading
frame was then isolated using PCR (30 cycles of: 95°C denaturing [30 sec], 55°C annealing
[1 min], 72°C extension [1 min]) using the following primers: sense: 5’- TAC TTC CAA TCC
AAT GCG TCT TCT CGA GGT TAC TAC CAT GGT ATT-3’ and antisense: 5’- TTA TCC
ACT TCC AAT GCG CTA CTT GTA CAG CTC GTC CAT GCC GAG AGT-3’ and then
subcloned into an N-terminal 6xHis-tagged vector using a ligation-independent strategy
previously described (19).
Protein production
His6-tagged N-terminal truncated human Gαi1 (ΔN-Gαi1), as well as full-length Gαi2, Gαi3,
and GαoA subunits, were purified from E. coli as previously described (20,21). His6-tagged
RGS12 RGS domain (aa 702 – 846 of SwissProt O08774) was cloned into pMCSG7 using a
ligation-independent cloning strategy (19) and purified as described for Gαi1. His6-tagged
human RGS16 (aa 53–190; ref. 22) was prepared from the expression construct pLIC-SGC1-
RGS16-s001 obtained from SGC (Oxford), per their published protocol (PDB ID 2BT2).
Transducin heterotrimer and PDE6 were purified from bovine retinas as described previously
(23); urea-treated photoreceptor membranes used as the source of photoactivated rhodopsin
were purified from bovine retinas as previously described (24).
Surface plasmon resonance
SPR binding assays were performed at 25°C using a BIAcore 3000. N-terminally biotinylated
KB-1753 or PDEγ(63–87) peptides (diluted to 0.1 µg/ml in BIA-run buffer [10 mM HEPES
(pH 7.4), 150 mM NaCl, 10 mM MgCl2, 0.005% NP40]) were coupled to flow cells of
streptavidin biosensors (Biacore) to a surface density of ~500 RU. Gα subunits were diluted
in BIA-run buffer in the presence of 100 µM GDP, 100 µM GDP plus 30 µM AlCl3 and 10
mM NaF, or 100 µM GTPγS and incubated at room temperature for 2 hours. Gα subunits in
desired nucleotide states (30 µL) were then injected over flow cells at 10 µL/min, followed by
a 300 s dissociation phase. To correct for nonspecific binding and buffer-shift artifacts, binding
curves from a surface containing a control peptide (mNOTCH1; ref. 25) were subtracted from
all binding curves. Surfaces were regenerated with two 10 µL injections of 500 mM NaCl plus
25 mM NaOH at 20 µL/min. BIAevaluation 3.0 was used for binding curve and kinetic
analyses. Dissociation constants (KD) were determined by saturation binding as previously
described (20,21).
Crystallization and structure determination
ΔN-Gαi1 protein (25 mg/ml in [20 mM Tris (pH 7.5), 1 mM MgCl2, 20 mM NaCl, 1 mM DTT,
5% glycerol, 10 µM GDP, 30 µM AlCl3, 10 mM NaF]) was incubated with a 1.5-fold molar
excess of KB-1753 at room temperature for 5 min prior to screening. Initial crystals were
obtained in condition 28 of the PEG-Ion Screen (Hampton Research) and refined to final
crystallization conditions of 15% PEG-8000 and 0.3 M calcium acetate using the vapor
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diffusion method with 8 µL hanging drops of a 1:1 volume ratio of protein to buffer. Crystals
formed in 2–4 days at 4°C in the space group P3221 (a = b = 103.13 Å, c = 206.99 Å; α = β =
90°, γ = 120°) with two Gαi1/KB-1753 heterodimers in the asymmetric unit. Crystals were
cryoprotected in crystallization buffer supplemented with 20% glycerol for ~1 min, then
submerged in liquid N2. A 2.8 Å native data set was collected at Brookhaven National
Laboratories using the x29 beamline. Data was scaled and indexed using HKL2000 (26). The
structure of Gαi1·GDP·AlF4− (PDB ID 1GFI), excluding waters, GDP, and AlF4−, was used
for molecular replacement (27). Initial solutions were found with correlation coefficients of
57.5 and starting R-factor of 47.6, which was reduced to 39.7 with an initial round of
refinement. Model building was completed using O (28), with successive rounds of simulated
annealing, minimization, B-group, and rigid body refinements being completed by CNS (29).
Noncrystallographic symmetry restraints were used in initial cycles of refinement, and both
Gαi1/KB-1753 dimers were essentially identical. All electron density map calculations were
completed with CNS. The N-terminal residues 25–32 of Gαi1 were disordered along with
residues 112–121 in the αB-αC loop of the all-helical domain; these segments were excluded
in the final Gαi1/KB-1753 model. All structural images were generated using PyMol (DeLano
Scientific, San Carlos, CA).
PDE6 activity assays
PDE6 activity was measured as described (30). Briefly, illuminated ureatreated photoreceptor
membranes (20 µl; 10 µM rhodopsin final), a source of photoexcited rhodopsin, were
reconstituted with purified transducin (1 µM) at room temperature in buffer containing 10 µl
GTPγS, 100 mM NaCl, 8 mM MgCl2 and 10 mM Tris-HCl (pH 7.8). When needed, 20 µM of
wildtype or mutant KB-1753 peptide was also added. PDE6 (0.05 µM) was added immediately
before the reaction was initiated by 10 µl [3H]cGMP (2.5 mM containing ~105 dpm/sample)
and terminated by addition of 100 µl 0.1 M HCl. The mixture was then neutralized by 100 µl
of 0.1 M Tris and incubated with 75 µl of king cobra snake venom (1 mg/ml) for 1 h to convert
GMP to guanosine. The solution was then passed through an anion-exchange DEAE-Sepharose
column to separate guanosine from cGMP, and washed twice with 0.8 ml of H2O. The eluent
was mixed with 10 ml ScintiSafe cocktail and radioactivity was measured by scintillation
counting.
GTPase assays
Single-turnover GTPase assays with Gαi1 were conducted as described (31). Briefly, 100 nM
Gαi1 was incubated at 30°C for 15 min in buffer C (50 mM Tris pH 7.5, 0.05% C12E10, 1 mM
DTT, 5 µg/ml BSA, 10 mM EDTA, 100 mM NaCl) containing ~1×106 cpm of [γ-32P]-GTP
(6000 Ci/mmol). Samples were then placed on ice for 5 min. Reactions (on ice) were initiated
by adding 10 mM MgCl2 (with 100 µM GTPγS) and timed reaction aliquots were quenched
by charcoal slurry (containing 20 mM H3PO4, pH 3) followed by centrifugation (~4000 ×g for
10 min at 4°C). Supernatants with free [γ-32Pi] were analyzed by scintillation counting.
Background counts (in the absence of Gαi1) were subtracted from all experimental conditions.
Multiple-turnover GTPase assays with Gαt were conducted as described (32). Briefly,
illuminated urea-treated photoreceptor membranes were mixed with transducin at room
temperature in a buffer containing 100 mM NaCl, 8 mM MgCl2, 10 mM Tris HCl pH 7.8 and
1 mM DTT. The reaction was started by the addition of 10 µl of [γ-32P]GTP at desired
concentration (final concentration 20 µM; approximately 105 dpm/sample) to 20 µl of
membranes (final concentrations of 10 µM rhodopsin and 1 µM transducin) supplemented by
additional proteins and/or peptides when needed. The reaction was stopped by 100 µl of 6%
perchloric acid. 32Pi formation was measured with activated charcoal. In the experiment
addressing the effect of PDEγ on RGS16 GAP activity, PDEγ (63–87) peptide was used instead
of the full length PDEγ because this peptide completely substitutes for PDEγ in RGS protein
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regulation but, unlike PDEγ, does not block repetitive transducin activation by rhodopsin
(33).
Fluorescence resonance energy transfer (FRET) assays
FRET assays for Gα/RGS interaction, along with purification of Gαi1-CFP and YFP-RGS4,
were completed as described (34). Gαi1-CFP was diluted in 10 mM Tris pH 8.0, 1 mM EDTA,
10 mM MgCl2, 150 mM NaCl, and 10 µM GDP. Experiments on the effects of AlF4− activation
were performed in buffer supplemented with 30 µM AlCl3 and 10 mM NaF. Measurements
were made with a LS-55B spectrofluorimeter (Perkin-Elmer). Emission scans were performed
at 20 nm/min using excitation of 433 nm, with slit widths of 5 nm. Emission maxima used for
CFP and YFP were 474 nm and 525 nm, respectively. For peptide competition experiments,
Gαi1 (200 nM) was allowed to incubate in the quartz cuvette with wildtype or mutant KB-1753
(2 µM) for 2 min prior to adding YFP-RGS4.
RESULTS
Identification of an activated-state-selective Gα binding peptide
To identify peptides capable of interacting with Gα selectively in the activated conformation,
we performed phage display analysis as previously described for peptides that bind inactivated,
GDP-bound Gα (9,10). Of the GTPγS-dependent Gαi1 binding peptides obtained, seven
peptides shared a consensus sequence of three hydrophobic residues centered around
tryptophan and flanked by glycines (Figure 1A). A MOTIF search (http://motif.genome.jp/)
of the Swiss-Prot protein database (35) with the degenerate sequence motif G-[IV]-W-
[ILMSVW]-G revealed 166 proteins bearing this peptide signature across all represented
genomes, but none was a known G-protein effector (data not shown). From this family of seven
peptides, the longest and most avid binder, KB-1753, became the focus of our current efforts.
To quantitate the nucleotide-dependent interaction of KB-1753 with Gαi1, we performed
surface plasmon resonance (SPR) measurements on a streptavidin biosensor coated with
biotinylated KB-1753. Injection of Gαi1·GDP·AlF4− or Gαi1·GTPγS analytes yielded robust
binding to KB-1753, whereas Gαi1·GDP showed no detectable interaction (Figure 1B). To
assess the affinity of these interactions, dissociation constants (KD values) were obtained by
saturation binding using a previously described technique (20,21). As shown in Figure 1C,
Gαi1 in both the transition state (GDP·AlF4−) and activated state (GTPγS) interacts with
KB-1753 with low micromolar affinity. KB-1753 bound with highest affinity to
Gαi2·GDP·AlF4−, nearly 10-fold better than either Gαi1 or Gαi3 (Figure 1C). No appreciable
affinity was detected for the GDP-bound conformation of any of these Gαi subunits, confirming
the results of the original phage selection (10). A chimeric Gα subunit that closely mimics
transducin (“αT*” in which the corresponding region from Gαi1 was inserted between residues
215 and 294 of Gαt; herein denoted Gαt/i1) (36) also interacted with KB-1753 in a nucleotide-
dependent manner. Interestingly, no detectable affinity was observed for the closely related
GαoA subunit nor the more divergent G-protein, Gαs (Figure 1C).
Overall structure of Gαi1·GDP·AlF4−/KB-1753
To understand the molecular details of the nucleotide-dependent interaction of KB-1753 with
Gα, we determined the structure of KB-1753 bound to Gαi1·GDP·AlF4− by X-ray diffraction
crystallography (Table 1). The conformation of Gα·GDP·AlF4− closely resembles that of
Gα·GTPγS (37,38), and AlF4− addition activates Gα signaling in vitro (39). The overall
structure of Gαi1 consists of two principal lobes: a Ras-like domain similar to the monomeric
GTPase fold and an additional all-helical domain (11); the guanine nucleotide binding pocket
lies between these two domains. The planar anion AlF4−, GDP, and Mg2+ are all found in the
Gαi1/KB-1753 structure as predicted (Figure 2A). Three flexible ‘switch’ regions, responsible
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for the conformational changes involved in the guanine nucleotide cycle (11), aid in the binding
of AlF4− and Mg2+ (Figure 2A).
Two nearly identical Gαi1/KB-1753 dimers exist in the asymmetric unit with an r.m.s.d. of
0.64 Å. Residues Arg-3 through Glu-13 of the KB-1753 peptide (S1SRGYYHGI
WVGEEGRLSR19) were sufficiently ordered to confidently model based on electron density
(Figure 2B,C). KB-1753 binds within the Ras-like domain of Gαi1 in a highly conserved
hydrophobic cleft formed by the α2 (switch II) and α3 helices (Figure 2). This cleft represents
the proposed effector-binding site for Gαi1 (40) and suggests that KB-1753 binds in an
‘effector-like’ mode to activated-state Gα (see below). Notably, binding of KB-1753 does not
significantly alter the conformation of Gαi1 as the overall r.m.s.d. between bound and unbound
structures was calculated to be 0.81 Å. Hydrophobic residues dominate the Gαi1/KB-1753
binding interface, including Ile-9 of KB-1753, which lies buried within the hydrophobic pocket
created by Gαi1 residues Trp-211 and Phe-215. Conservative replacement of this isoleucine
with valine leads to a five-fold decrease in binding affinity, whereas alanine substitution at
Ile-9 (in combination with the critical Trp-10, see below) completely abolishes interaction of
KB-1753 with Gαi1 (Figure 3B). Additional van der Waals contacts are made between His-7
and Ile-212 within this pocket. Other KB-1753/Gαi1 contacts include Val-11/Arg-208, Trp-10/
Lys-248, Trp-10/Ser-252, His-7/Asn-256, and Gly-8/Asn-256 (Figure 2B and Figure 3A).
When bound to Gαi1, KB-1753 assumes a hairpin secondary structure centered about residues
Tyr-6 and His-7, with several stabilizing intramolecular contacts aiding the adoption of this
hairpin (e.g., Figure 2B). The position of the imidazole nitrogen of His-7 raises the possibility
of a cation-pi interaction with Tyr-6 at the hinge of the hairpin loop. Mutation of this histidine
results in a seven-fold reduction in binding affinity (“H7F”; Figure 3C). Other intramolecular
contacts within the bound conformation of KB-1753 include Gly-4/Val-11, Gly-4/Gly-12,
Tyr-5/Trp-10, Tyr-6/Ile-9, Tyr-6/Val-11 (Figure 2B and Figure 3A). Figure 2C illustrates the
electron density depicting the confidence of model building of KB-1753 and its interaction
with Gαi1.
Molecular basis of nucleotide-dependent interaction
Binding of an activating nucleotide such as GTP, GTPγS, or GDP·AlF4− to Gα induces specific
structural changes in the three switch regions. The conformations of these switch regions are
very similar in the Gα·GDP·AlF4− and Gα·GTPγS forms (11), explaining the ability of
KB-1753 to bind these two conformations equipotently. In these active conformations, Arg-208
in switch II makes a critical contact with Glu-245 of the α3 helix, just beyond switch III, which
helps stabilize the switch II conformation (37,38). Interestingly, the indole nitrogen of Trp-10
in KB-1753 exploits this interaction and makes contacts with both Arg-208 and Glu-245
(Figure 2B). These interactions may thus partially contribute to the selective nature of KB-1753
binding to activated Gα, as switch II is entirely disordered in the structure of Gα·GDP likely
due to a lack of stabilization with switch III (11). Indeed, this conserved glutamate residue
makes contacts with effectors in the structures of Gαt/PDEγ, Gα13/p115-RhoGEF, and Gαq/
GRK2 dimers, although the contributing effector residues are not tryptophan as seen here with
KB-1753 (6). However, the exact degree to which this interaction aids in the nucleotide
selectivity of KB-1753 cannot be inferred as Trp-10 may play other critical roles in the Gα/
KB-1753 interaction, such as stabilization of the peptide conformation.
The hydrophobic binding pocket created by Trp-211 and Phe-215 likely also contributes to the
nucleotide selectivity of KB-1753. The overall architecture of this pocket perfectly
accommodates the Ile-9 of KB-1753. A highly conservative replacement of Ile-9 with valine,
lacking a single methyl extension, results in a loss of binding affinity (“I9V”; Figure 3C).
Furthermore, given the inherent flexibility of switch II in the GDP-bound state (11), the
integrity of this pocket would be compromised in the inactive conformation. Our recent
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structural analysis of Gαi1 bound to a GDP-selective peptide, KB-752, revealed a similar mode
of interaction with the Trp-211/Phe-215 pocket (10). In the case of KB-752, however, a
tryptophan from the peptide was perfectly accommodated by the Trp-211/Phe-215
hydrophobic pocket only in the inactive conformation, given that active conformations present
steric clash with the larger tryptophan side chain (10). These results underscore the critical
involvement of the hydrophobic pocket formed from the α2/α3 helices in binding these
regulatory peptides and dictating their nucleotide selectivities.
KB-1753 blocks Gα/effector interaction
The binding site for KB-1753 on Gαi1 lies in the putative effector-binding region. Mutational
analyses implicate this region as the binding site on Gαi1 for adenylyl cyclase (40). Moreover,
crystal structures of Gαs/adenylyl cyclase and Gαt/PDEγ have established the α2/α3 pocket,
along with the α2/β4 loop, as the effector binding site for these G-protein subunits (3,4). As
Gαt and Gαi1 are members of the same Gα subfamily, we focused on the Gαt/PDEγ interaction
to validate that KB-1753 binds to the Gα effector-binding site and could thus serve as a unique
effector antagonist. The Gαi1/KB-1753 and Gαt/PDEγ structures indicate similar modes of
Gα interaction between these two peptides (Figure 4A). We first demonstrated using SPR that
a soluble Gαt/i1 chimera (containing Gαi1 sequence from residues 215 [end of α2 helix] through
294 [start of α4 helix]; ref. 36) could bind both KB-1753 and a peptide comprising residues
63–87 of PDEγ (Figure 4B inset). We next tested whether KB-1753 and PDEγ exhibit mutually
exclusive binding to Gαt/i1. As expected, preincubation of Gαt/i1 with free KB-1753 peptide
inhibited (in a dose-dependent manner) binding of Gαt/i1·GDP·AlF4− to biotinylated KB-1753
immobilized on the SPR biosensor (data not shown). Preincubation with KB-1753 also
abrogated binding of Gαt/i1·GDP·AlF4− to a biotinylated PDEγ peptide surface (Figure 4B).
These results establish that KB-1753 competes for effector (PDEγ) binding to Gαt/i1,
suggesting that KB-1753 could serve as an effector antagonist in the transducin/PDE signaling
pathway.
We thus tested whether KB-1753 could perturb wildtype Gαt interaction with, and signaling
to, cGMP phosphodiesterase (PDE6) by reconstituting these proteins with photoreceptor
membranes containing light-activatable rhodopsin, the receptor upstream of transducin. As
part of the phototransduction signaling pathway, Gαt·GTP activates PDE6 by binding directly
to PDEγ and releasing the inhibitory constraint which PDEγ imposes on the α and β catalytic
subunits of PDE6 (41).We tested whether KB-1753 could impair PDE6 activation by Gαt·GTP
by measuring the steady-state rate of cGMP degradation to GMP. Rhodopsin-activated
transducin was observed to stimulate degradation of cGMP in reconstituted ROS membranes
(Figure 4C). KB-1753, but not the I9A/W10Asubstituted peptide, nearly abolished the
stimulation of PDE6 cGMP hydrolysis activity (Figure 4C). Together, the results from SPR
competition binding and PDE6 activity assays confirm the ability of KB-1753 to interdict
GPCR-mediated signaling through activated G-proteins to effector enzyme activity and
suggest that KB-1753 could serve as a novel tool for antagonizing these signaling pathways.
KB-1753 interferes with RGS protein GAP activity
We also reasoned that, by binding to the transition-state mimetic form of Gα
(Gα·GDP·AlF4−), KB-1753 may alter the intrinsic and/or RGS protein-stimulated GTPase
activity of Gαt and Gαi1. The experiments conducted with wildtype Gαt reconstituted with
photoreceptor membranes revealed the presence of both effects (Figure 5A). Addition of
KB-1753 caused a nearly 2-fold increase in the basal rate of Gαt GTPase activity. This activity
may arise from stabilization of switch II by KB-1753 in a conformation suitable for the catalytic
Gln-204 of Gα to more efficiently participate in GTP hydrolysis. Addition of KB-1753 also
caused an ~40% reversal of GTPase acceleration by an RGS protein, RGS16, previously shown
to act on Gαt (42). Neither effect was observed with control I9A/W10A-substituted peptide.
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Partial inhibition of RGS16 GAP activity by KB-1753 was very similar to well-documented
partial inhibition caused by PDEγ (lowest bar in Figure 5A; see refs. (43, 44) for original
observation).
Comparing the Gα/KB-1753 and Gα/RGS4 structures reveals no significant alterations in the
overall Gα backbone (r.m.s.d. of 0.68 Å) nor of the critical catalytic residues R178, T181, and
Q204. However, space-filling models of KB-1753 and RGS4 indicate that, although KB-1753
binds to the effector-binding region of Gα, which is exclusive from the RGS protein-binding
interface (5,6), the C-terminus of KB-1753 could sterically hinder RGS protein access to its
Gα binding site (Figure 5B). KB-1753 significantly blocked the GAP activity of RGS12 on
Gαi1 (Figure 5C,D), suggesting that KB-1753 interferes with RGS protein binding. We also
observed a small peptide-dependent acceleration of basal Gαi1 GTPase activity (Figure 5C)
although, unlike in the case of wildtype Gαt (Figure 5A), this effect was not statistically
significant. Using a fluorescence resonance energy transfer (FRET)-based assay for Gα/RGS
protein interactions (34), we confirmed that KB-1753 is able to block the direct interaction
between RGS4 and Gαi1 (Figure 5E). Thus, KB-1753 serves as a novel peptide inhibitor of
Gαi1/RGS protein interaction and RGS-mediated GAP activity in vitro.
A fusion of KB-1753 onto yellow fluorescent protein serves as a sensor for activated Gα
Fluorescent biosensors have become instrumental for investigating protein-protein interactions
as well as protein activation in real-time and visualizing the spatiotemporal aspects of signal
transduction in live cells (45,46). The ability of KB-1753 to bind only activated Gα makes it
a potentially useful tool for developing novel biosensors for G-protein activation. In an initial
test of this hypothesis, we employed FRET between chromatic variants of the Aequoria
victoria green fluorescent protein in which excitation of a donor cyan fluorescent protein (CFP)
in turn excites an acceptor yellow fluorescent protein (YFP) when these variants are within
defined distance constraints (~50 Å) (47). We subcloned the KB-1753 peptide sequence N-
terminal to YFP (KB-1753-YFP) to serve as a FRET acceptor for CFP-modified Gαi1 (Figure
5B; ref. 34). KB-1753-YFP underwent a robust FRET response with CFP-Gαi1, selectively in
the presence of aluminum tetrafluoride (Figure 6A, B) and with an affinity of ~750 nM (Figure
6C). Incubation of CFP-Gαi1 with excess unmodified KB-1753 (but not the I9A/W10A mutant)
blocked the FRET response (Figure 6B). These results validate KB-1753-YFP as a bona fide
FRET partner for detecting the activated conformation of CFP-tagged Gαi1 – a form of
KB-1753 that could be directly applied to in vivo settings (45,46).
DISCUSSION
The structural basis of G-protein regulation resides in subtle conformational changes in three
critical switch regions of the Gα subunit (11). Upon GDP release from the inactive, Gβγ-
complexed conformation, Gα binds GTP and adopts the active conformation capable of
regulating effector molecules. Regulatory proteins (such as RGS proteins and GoLoco
proteins) exploit these distinct nucleotide-dependent conformations of Gα for their binding and
modulation of the nucleotide cycle (7,8,48). Here, we have described a peptide, KB-1753,
capable of interacting with specific Gα subunits solely in active conformations. The crystal
structure of this peptide bound to Gαi1·GDP·AlF4− reveals an ‘effector-like’ mode of binding,
relying on the specific conformation of the switch II helix. KB-1753 serves as an effector
antagonist as well as an inhibitor of RGS protein activity. These qualities make KB-1753 an
attractive new tool for studying G-protein signaling. The development of biosensors for
activated Gα using KB-1753 should open new avenues for both in vitro assay design and real-
time in vivo imaging of Gα activation.
Currently, available Gα/effector structures include Gαs/adenylyl cyclase, Gαq/GRK2, Gα13/
p115RhoGEF, and Gαt/PDEγ/RGS9 (3–6). Although Gαt belongs to the Gαi family, currently
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no specific structural analysis of a Gαi1–3/effector complex exists. Thus, the Gαi1/KB-1753
complex represents the first structural glimpse of Gαi1 engaged in an effector-like recognition
mode, albeit with a nonphysiological target. Based on the Gαs/adenylyl cyclase structure and
the pseudosymmetry of the C1 and C2 cytosolic lobes of adenylyl cyclase (3), mutational
analysis has revealed residues within the C1 lobe of type V adenylyl cyclase (ACV) critical to
Gαi1 regulation (49). Specifically, these critical C1 lobe residues reside in the α1/α2 and the
α3/β4 segments of ACV, with the latter segment proposed to bind within the switch II/α3 cleft
of Gαi, the binding site for KB-1753. However, no significant sequence similarity was observed
between KB-1753 and the α3/β4 loop of ACV. A sequence of SLVREMTGVNV within the
ACV α3/β4 loop has been implicated in binding the switch II/α3 cleft of Gαi; bolded, underlined
residues indicate particular positions that, when mutated, result in loss of Gαi-mediated
inhibition (49). Aside from a general hydrophobic character in this region of ACV that may
complement the hydrophobic cleft in Gα, no significant homology exists with KB-1753. Thus,
KB-1753 appears to be a unique sequence that exploits the same effector-binding region of
Gαi1, and suggests that diverse primary sequences in effectors may recognize a similar binding
motif within Gα. Indeed, the switch II/α3 cleft utilized by effectors is highly conserved among
Gα subfamilies (Figure 7) (3–6); therefore, diversity within effectors, either in primary
sequence or tertiary structure, must compensate for the common Gα binding groove to allow
for signaling specificity (6). This difficulty in defining Gα/effector specificity based on the
conserved nature of structurally-defined interactions has been previously discussed (6).
Another possibility is that additional regions of Gα define effector specificity by
complementing the conserved interactions within the switch II/α3 cleft. For example, regions
within the α4/β6 loop of Gαi2 (specifically 314RKDTKE319) have been implicated in the
interaction with adenylyl cyclase (40). However, KB-1753 makes no contact within this region
of Gα. Also, the α2/β4 and α3/β5 regions of Gα have been implicated in effector binding;
however, with the exception of Gαs, these sequences are also highly conserved (6). The ability
of KB-1753 to inhibit binding and signaling of wildtype transducin to PDE6, an effector to
which KB-1753 also lacks significant sequence similarity, signifies its effector-like mode of
binding to Gαi1 and further underscores the sequence diversity in effectors available for Gα
subunit recognition.
KB-1753 is a potentially attractive new tool for studying G-protein signaling. If modified to
allow cell penetration (e.g., ref. 50), KB-1753 could effectively block Gαi·GTP/effector
signaling while preserving receptor/heterotrimer coupling and Gβγ-mediated signaling, unlike
pertussis toxin which permanently impairs Gαiβγ coupling and signaling via ADP-ribosylation
(51) or of siRNA-mediated Gnai transcript silencing which can result in compensatory
upregulation of other Gαi/o family members (52). The selective interaction of KB-1753 with
Gαi subunits over Gαo (Fig. 1B) would provide another advantage in interrogating GPCR
coupling specificity over pertussis toxin, the latter acting nonspecifically on all Gαi/o subfamily
members except Gαz (53). The ability of KB-1753 to block RGS protein binding and resultant
GAP activity highlights yet another potential usefulness of this novel peptide.
Biosensors capable of visualizing the spatiotemporal aspects of protein activation and protein-
protein interactions have become indispensable tools for studying signal transduction events
within the context of live cells (47,54). Several studies using CFP/YFP FRET and related
techniques have investigated GPCR signaling dynamics (55–58). Studies interrogating
heterotrimer activation have used designs wherein activation leads to a reduction in FRET
response due to the dissociation of a Gα-CFP and Gβγ-YFP coupled pair, for example, ref.
(57). Although innovative and informative, these studies are limited by their reliance on a
loss of FRET response which presents specific technical challenges (such as correcting for
photobleaching artifacts) and limits the ability to track the spatiotemporal aspects of Gα
signaling once activated. Our KB-1753-YFP, however, presents an attractive alternative design
that produces an increase in FRET response following Gα activation (Figure 6) and should
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allow resolution of the spatiotemporal dynamics of activated Gα signaling. Moreover, as Gα
becomes deactivated, a loss of FRET response would be expected, given that KB-1753-YFP
binds selectively to only the activated form. Thus, a FRET-based approach with KB-1753-YFP
could report both the activation and deactivation dynamics of Gα signaling potentially
improving the resolution of previous studies. We are now avidly working towards this goal.
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Figure 1. Selective binding of KB-1753 to Gα subunits as measured by surface plasmon resonance
(SPR)
(A) Sequences of seven peptides, including KB-1753, with a shared sequence (grey) isolated
by phage-display based on selective binding to immobilized Gαi1·GTPγS (10). (B) 10 µM
Gαi1 protein (“analyte”), in each of three nucleotide-bound states as indicated, was injected
over immobilized, biotinylated KB-1753 peptide. Non-specific binding (~200 RU) to a control
peptide surface was subtracted from each curve. (C) Indicated Gα subunits, including a chimera
between Gαtransducin and G αi1 (“Gαt/i1”), were separately injected at increasing concentrations
(0.01 – 50 µM) over immobilized KB-1753 to determine dissociation constants (KD) for each
interaction pair as obtained by saturation binding analysis (20,21). No binding (KD > 1000
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µM) was seen with any G α in the GDP-bound state. “KD > 50 µM” denotes interactions with
minimal binding responses observed only at saturating concentrations of Gα greater than 50
µM. n.d., not determined.
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Figure 2. Structural features of the Gαi1/KB-1753 interaction
(A) KB-1753 peptide (red, with side-chains) is bound between the α2 (“switch II”) and α3
helices of the Gαi1 Ras-like domain (blue; switch regions in green). No contact is made between
KB-1753 and the all-helical domain (yellow), GDP (magenta), AlF4− (grey), or magnesium
(orange). (B) Representative inter- and intramolecular contacts between Gαi1 (blue; switch
regions in green) and KB-1753 (tan) residues are shown in black dotted lines. All contacts
shown or discussed in the text were selected based on a maximum distance cutoff of 3.7 Å.
(C) Stereoview of experimental electron density for KB-1753 bound to Gαi1, shown as a 2Fo-
Fc simulated annealing composite omit map generated with 5% overall model omitted and
contoured at 1 σ (electron density shown in white cage). The region highlighted is the entire
peptide density (model in red) lying below the α3 helix (model in blue) and above switch II
(model in green).
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Figure 3. Effects of amino-acid substitutions on KB-1753 binding affinity
(A) Summary of intrapeptide and Gαi1 contacts made by KB-1753 peptide residues. (B) N-
terminally biotinylated KB-1753 peptides, either with wildtype sequence or mutated (Ile-9 and
Trp-10 replaced with alanine), were immobilized on separate streptavidin-coated flow cells
and 2 µM of Gαi1·GDP·AlF4− protein (“analyte”) was injected over both surfaces. Non-specific
binding to a control peptide was subtracted from each curve. (C) Dissociation constants (KD
in µM) for the interaction between Gαi1, in indicated nucleotide state, and wildtype or mutant
KB-1753 peptides immobilized on SPR surfaces. Other parameters are described in Figure 1C.
Johnston et al. Page 17













Figure 4. KB-1753 acts as an effector antagonist
(A) Surface rendering of Gαi1·GDP·AlF4− (grey) with contact points highlighted for KB-1753
alone (green), PDEγ alone (blue), or shared between both interactors (yellow). (B) Wildtype
KB-1753 competes with PDEγfor binding to Gα, but not the I9A/W10A mutant peptide nor
the Gαi1·GDP-selective peptide KB-752. AlF4−-activated Gαt/i1 protein (8.5 µM) was pre-
incubated with indicated concentrations of competitor peptide prior to injection over a
streptavidin SPR surface bearing biotinylated PDEγ(63–87). Inset: SPR surfaces coated with
either biotinylated KB-1753 or PDEγ peptide bind with equivalent affinity to the Gαt/i1 chimera
bound to GDP and AlF4−. (C) Rates of cGMP hydrolysis to GMP by transducin-activated
PDE6 (0.05 µM) in the absence (control) or presence of 20 µM wild type or mutant KB-1753
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peptides were calculated from linear fits of the data: control = 9.2 µM GMP produced per
second; wild type KB-1753 = 1.1 µM/second; I9A/W10A mutant KB-1753 = 9.1 µM/second.
The data are taken from one of three similar experiments.
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Figure 5. KB-1753 interferes with the RGS domain/Gα interaction and RGS -mediated GAP
activity
(A) Steady-state rates of GTP hydrolysis by rhodopsin-activated transducin (1 µM) were
measured in the absence or presence of 1 µM RGS16 protein, 25 µM PDEγ(63–87), and/or 20
µM wild type or mutant KB-1753 peptide, as indicated. GTP hydrolysis rates were determined
from linear fits of reaction time courses; the data are averaged from two similar experiments
with error bars representing SEM. (B) Surface rendering of Gαi1·GDP·AlF4− (grey) bound to
RGS4 (cream; derived from PDB ID 1AGR) and overlaid with a space-filling representation
of KB-1753 (red). Note that contacts made to Gαi1·GDP·AlF4− by RGS4 (blue) and by
KB-1753 (green) are not overlapping, yet steric hindrance is predicted between bound
KB-1753 and the α5/α6 loop of RGS4 (aa 120–123 shown in space-fill). (C) Single-turnover
GTP hydrolysis assay using [γ-32P]GTP-labelled Gαi1 (0.1 µM) in the absence or presence of
either 0.1 µM RGS12 RGS domain or 1 µM KB-1753 or both. (D) Dose dependence of wildtype
KB-1753-mediated inhibition of RGS12 RGS domain GAP activity, as measured in single-
turnover GTPase assays performed as in panel B. The I9A/W10A mutant KB-1753 shows no
inhibitory activity. (E) Effect of 2 µM KB-1753 peptide (wildtype or I9A/W10A mutant) on
AlF4−-dependent FRET between 0.2 µM Gαi1-CFP and 0.2 µM YFP-RGS4 fusion proteins;
FRET was quantified by the emission ratio (525 nm/474 nm), representing the ratio between
YFP emission and CFP emission maxima upon excitation at 433 nm.
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Figure 6. A KB-1753/yellow fluorescent protein fusion acts as a sensor for activated Gαi1
(A) 200 nM of Gαi1-CFP and/or 500 nM of KB-1753-YFP fusion proteins were added to
cuvettes containing assay buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 10 mM MgCl2, 150 mM
NaCl, 10 µM GDP, 30 µM AlCl3, and 10 mM NaF; the latter two reagents forming the Gα
activator aluminum tetrafluoride) and allowed to incubate for 60 seconds before emission scans
(450 – 600 nm) were taken using an excitation wavelength of 433 nm at 20 nm/minute and slit
widths of 5 nm. Data shown are uncorrected fluorescence measurements under each indicated
condition. (B) FRET between 0.5 µM KB-1753-YFP and 0.2 µM Gαi1·GDP·AlF4−-CFP is
inhibited by pre-incubation of Gα with 2 µM wildtype KB-1753 peptide; preincubation with
2 µM of the I9A/W10A mutant was observed to have no effect on the emission ratio. (C) Dose-
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and nucleotide-state-dependent FRET between 0.2 µM Gαi1-CFP and indicated concentrations
of KB-1753-YFP fusion. Data are expressed as “corrected FRET” obtained by subtracting the
emission of KB-1753-YFP alone from each FRET condition. Apparent dissociation constant
obtained for the KB-1753-YFP/Gαi1·GDP·AlF4−-CFP interaction: KD = 0.76 ± 0.08 µM (best-
fit ± std. error).
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Figure 7. Conserved structural features of Gα engagement by effectors and by KB-1753
(A) Multiple sequence alignment derived from Clustal-X (59) of human Gαi1 (GenBank
AAM12619), bovine Gαt (SwissProt P04695), human Gαo (SwissProt P09471), human Gα13
(GenBank NP_006563), and bovine Gαs (SwissProt P04896) sequences, highlighting locations
of switch II and switch III, as well as conservation of three hydrophobic residues involved in
effector engagement (green boxing). Burial of a key hydrophobic residue of an effector (red)
within a conserved hydrophobic cleft between switch II (α2) and α3 helices of activated Gα
(blue; switch regions in green) is apparent in the crystal structures of Gαs·GTPγS bound to the
second cytoplasmic domain of type II adenylyl cyclase (AC) (panel B; ref. 3),
Gαt·GDP·AlF4− bound to the gamma subunit of cGMP phosphodiesterase (PDEγ) (panel C;
Johnston et al. Page 23













ref. 4), the N-terminal RGS domain of the RhoA guanine nucleotide exchange factor
p115RhoGEF interacting with GDP·AlF4−-bound Gα13/i-5, a chimeric Gα subunit based on
Gαi1 but containing the three switch regions and the helical domain of Gα13 (panel D; ref. 5),
and Gαi1·GDP·AlF4− bound to the KB-1753 peptide (panel E; this study).
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Table 1
Data collection and refinement statistics
Data collectiona
Space group P3221
No. of molecules per asymmetric unit 2
Unit cell dimensions
  a, b, c (Å) 103.13, 103.13, 206.99
  α, β, γ (°) 90, 90, 120
Wavelength (Å) 1.1
Resolution (Å) 50-2.8 (2.9-2.8)
Linear R-factorb 0.093 (0.416)
Square R-factorc 0.065 (0.330)
Mean I/σd 23.1 (2.7)
Completeness (%) 94.1 (61.0)
Redundancy 6.4 (4.5)
Refinement
Resolution (Å) 50-2.8 (2.82-2.8)
No. reflections (working/test set) 25452/2824
Rwork/Rfree (%)
e 27.9/30.7
No. of non-hydrogen atoms
  Protein 5090
  GDP/AlF/Mg 56/10/2
  Water 30
R.m.s. deviations
  Bonds (Å) 0.01
  Angles (°) 1.22
Average B-factor 51.4





Native data set collected at Brookhaven National Laboratory synchrotron X-ray source on Beamline x29. Numbers in parentheses pertain to the highest
resolution shell.
b
Linear R-factor = Σ(|I - |)/Σ(I)
c
Square R-factor = Σ(|I - |)2/Σ(I)2
d
<I/σI>, Mean signal-to-noise, where I is the integrated intensity of a measured reflection and σI is the estimated error in measurement.
e
Rwork = Σ(|Fp - Fp(calc)|)/ΣFp, where Fp and Fp(calc) are the observed and calculated structure factor amplitudes. Rfree is calculated similarly using
test set reflections never used during refinement.
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